Can you provide the last earnings date for PROTAGONIST THERAPEUTICS INC?
PROTAGONIST THERAPEUTICS INC (PTGX) last reported earnings on 2/25/2026.
NASDAQ:PTGX • US74366E1029
Past quarterly earnings results for PROTAGONIST THERAPEUTICS INC (PTGX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.69 | -0.54 | -28.03% | -134.85% | 7.437M | 9.105M | -18.32% | -95.64% |
| Q3 2025 | -0.62 | -0.65 | 4.88% | -14.81% | 4.712M | 3.709M | 27.04% | 0.79% |
| Q2 2025 | -0.55 | -0.59 | 6.78% | -10.00% | 5.546M | 6.942M | -20.11% | 33.09% |
| Q1 2025 | -0.19 | -0.24 | 19.40% | -105.83% | 28.321M | 31.053M | -8.80% | -88.89% |
| Q4 2024 | 1.98 | 0.33 | 504.52% | 350.00% | 170.638M | 51.36M | 232.24% | 184.40% |
| Q3 2024 | -0.54 | -0.62 | 12.85% | 6.90% | 4.675M | 2.113M | 121.25% | - |
| Q2 2024 | -0.50 | -0.61 | 18.53% | 26.47% | 4.167M | 8.16M | -48.93% | - |
| Q1 2024 | 3.26 | 1.22 | 167.72% | 586.57% | 254.953M | 122.4M | 108.29% | - |
| Q4 2023 | 0.44 | -0.03 | 1,399.31% | 163.77% | 60M | 40.8M | 47.06% | - |
| Q3 2023 | -0.58 | -0.71 | 18.05% | 9.38% | 8.5M | -100.00% | - | |
| Q2 2023 | -0.68 | -0.66 | -2.99% | 19.05% | - | -100.00% | ||
| Q1 2023 | -0.67 | -0.74 | 9.61% | -55.81% | 2.04M | -100.00% | -100.00% | |
| Q4 2022 | -0.69 | -0.65 | -5.98% | 10.39% | 5.1M | -100.00% | -100.00% | |
| Q3 2022 | -0.64 | -0.89 | 27.71% | 8.57% | - | -100.00% | ||
| Q2 2022 | -0.84 | -0.95 | 11.13% | -21.74% | 860K | 390.997K | 119.95% | -62.11% |
| Q1 2022 | -0.43 | -0.64 | 32.91% | 20.37% | 25.72M | 17.391M | 47.89% | 315.51% |
| Q4 2021 | -0.77 | -0.80 | 3.53% | -60.42% | 8.62M | 5.173M | 66.63% | 52.57% |
| Q3 2021 | -0.70 | -0.68 | -2.43% | -233.33% | 10.29M | 1.778M | 478.74% | -21.51% |
| Q2 2021 | -0.69 | -0.56 | -23.64% | -13.11% | 2.27M | 5.275M | -56.97% | -63.50% |
| Q1 2021 | -0.54 | -0.58 | 6.79% | 25.00% | 6.19M | 1.53M | 304.58% | 69.59% |
| Q4 2020 | -0.48 | -0.49 | 1.55% | - | 5.65M | 3.188M | 77.23% | - |
| Q3 2020 | -0.21 | -0.62 | 66.39% | - | 13.11M | 2.193M | 497.81% | - |
| Q2 2020 | -0.61 | -0.61 | -0.51% | - | 6.22M | 2.584M | 140.71% | - |
| Q1 2020 | -0.72 | -0.71 | -2.01% | - | 3.65M | 1.51M | 141.72% | - |
Notes
PROTAGONIST THERAPEUTICS INC (PTGX) last reported earnings on 2/25/2026.
PROTAGONIST THERAPEUTICS INC (PTGX) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, PROTAGONIST THERAPEUTICS INC (PTGX) has beaten EPS estimates in 3 out of 4 releases.